Major Program
Supportive Care and Symptom Management
NCI Community Oncology Research Program
Research Group
Community Oncology and Prevention Trials
Sponsor
SWOG Cancer Research Network
Status
Completed
NCT ID
NCT01416688
RATIONALE: Questionnaires that patients can use to assess skin toxicities related to treatment may help identify the intermediate-and long-term effects of cetuximab, panitumumab, or erlotinib hydrochloride.
PURPOSE: This trial studies the validation of a cancer questionnaire for skin toxicities in patients with colorectal or lung cancer receiving cetuximab, panitumumab, or erlotinib hydrochloride.
PURPOSE: This trial studies the validation of a cancer questionnaire for skin toxicities in patients with colorectal or lung cancer receiving cetuximab, panitumumab, or erlotinib hydrochloride.
Intervention
assessment of therapy complications, psychosocial assessment and care, quality-of-life assessment
Condition
Colorectal Cancer, Dermatologic Complications, Lung Cancer, Therapy-related Toxicity
Investigators
Laurence H. Baker, DO, FACOI